701 | EFFICACY OF HIGH‐DOSE THIOTEPA, RITUXIMAB, AND POMALIDOMIDE AS A SALVAGE REGIMEN FOR RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Documenti analoghi

• 88 | TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY
  di: L. Nayak, et al.
  Pubblicazione: (2025)
• 704 | ORELABRUTINIB PLUS RITUXIMAB AND HIGH‐DOSE METHOTREXATE IN PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSED LARGE B‐CELL LYMPHOMA: A SINGLE‐ARM PHASE II STUDY
  di: F. Zhu, et al.
  Pubblicazione: (2025)
• 713 | CHEMOTHERAPY‐FREE THERAPY WITH RITUXIMAB, LENALIDOMIDE, AND POSELTINIB IN RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A MULTI‐CENTER, PHASE II STUDY
  di: D. H. Kim, et al.
  Pubblicazione: (2025)
• 343 | A PILOT STUDY OF AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
  di: C. Jacobson, et al.
  Pubblicazione: (2025)
• 695 | CLINICAL RESPONSE AND SAFETY FOR RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B CELL LYMPHOMA TREATED BY RADIOTHERAPY SEQUENTIAL GLOFITMAB
  di: J. Huang, et al.
  Pubblicazione: (2025)